Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PET-CT scans may help spot hidden lung cancer spread

NCT ID NCT05970913

Knowledge-focused Sponsor: Fudan University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether PET-CT scans can predict if non-small cell lung cancer has spread to nearby lymph nodes. Researchers will compare two types of PET-CT scans (using different tracers) with the actual results from surgery. The goal is to see if these scans can help doctors plan better treatments. The study involves 280 participants and is being run by Fudan University.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PET-CT scan (18F-FDG and 18F-FAPI tracers)
What this could lead to
If successful, this could help doctors better predict if lung cancer has spread to lymph nodes, potentially guiding more precise surgery and avoiding unnecessary procedures.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve outcomes. The results may not apply to all lung cancer patients, and the scans might not be accurate enough to replace current methods.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 280 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients had non small cell lung cancer who received pathological examination of lymph nodes

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Solitary tumor, or multiple tumors with only ground-glass nodules (GGNs) apart from the primary lesion. * Diameter of the primary lesion ≤5cm, with a CTR between 0.5 and 1. * Pathological confirmation of non-small cell lung cancer (NSCLC) either before or during surgery. * No prior radiotherapy or chemotherapy for initial treatment. * No history of malignant tumors. Exclusion Criteria: * Locally advanced or distant metastasis. * Pleural dissemination observed during surgery. * History of malignant tumors. * Received neoadjuvant therapy. * Histopathological examination reveals lung malignancies other than non-small cell lung cancer (NSCLC).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymph node metastasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lymphatic Metastasis metastatic malignant neoplasm in the lymph nodes non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymph node metastasis Non-small cell lung cancer Positron emission tomography

Contacts and locations

Locations

  • Shanghai Cancer Center

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.